anti-Syk, mAb (8H5)

Product description: Monoclonal Antibody. Recognizes the Human protein. Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol. Syk, Spleen tyrosine kinase, is expressed in a wide range of hematopoietic and non-hematopoietic cells and plays a key role in adaptive immune system, which is the immunoreceptor (B cell receptor and Fc-receptors) signaling pathways including Fcgamma receptor-mediated phagocytosis. In hematopoietic cells such as B and T lymphocytes, natural killer cells, mast cells, macrophages and platelets, Syk is involved in the proximal signaling downstream of activated immunoreceptors (e.g. BCR, TCR, Fc receptors) containing immunoreceptor tyrosine-based activation motifs (ITAMs) to which it binds using its tandem SH2 domains. Activated and autophosphorylated Syk then phosphorylates its specific substrates including other enzymes and adaptor proteins, orchestrating a complex series of cellular responses such as cell proliferation, differentiation, survival and phagocytosis. Positive effector of BCR-stimulated responses. Couples the B-cell antigen receptor (BCR) to the mobilization of calcium ion either through a phosphoinositide 3-kinase-dependent pathway, when not phosphorylated on tyrosines of the linker region, or through a phospholipase C-gamma-dependent pathway, when phosphorylated on Tyr-348 and Tyr-352. Thus the differential phosphorylation of Syk can determine the pathway by which BCR is coupled to the regulation of intracellular calcium ion

Alternate Names/Synonyms: SYK; p72-Syk; EC=2.7.10.2; Spleen Tyrosine Kinase; Tyrosine-Protein Kinase SYK

Product Type: Monoclonal Antibody

Clone: 8H5

Isotype: Mouse IgG1 kappa

Immunogen: Synthetic peptide.

Applications: ELISA, IP

Species Crossreactivity: Human

Formulation: Liquid. HEPES with 0.15M NaCl, 0.01% BSA, 0.03% sodium azide, and 50% glycerol.

Short Term Storage: +4°C

Long Term Storage: -20°C

Shipping: BLUE ICE

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C.

Lien vers la Fiche Technique

Literature References: 1) Turner M, et al, Immunol Today. 2000; vol.21(3):148-154. (General)2) Berton G, et al, Trends Immunol. 2005; vol.26(4):208-214. (General)3) Coopman PJ, Mueller SC. Cancer Lett. 2006; vol.241(2):159-173. (General)4) Navara CS Curr Pharm Des. 2004; vol.10(15):1739-1744. (General)